Purpose: To examine the effects of a single 10-mg dose of ML on physical performance in EIB− and EIB+ athletes.
Methods: Twenty-four male college ice hockey players performed two 6-min maximal work accumulation bouts on an electronically braked cycle ergometer in subfreezing conditions (−2.5 ± 0.4°C) 6–8 h after either ML or placebo (PL) to obtain total work accumulated (kJ); subjects were evaluated for EIB after each exercise trial.
Results: Eight (33%) subjects were identified as EIB+ (23.5 ± 13.35% fall in FEV1); 16 were EIB− (1.8 ± 3.03% fall in FEV1). ML provided a ∼50% protection against postexercise fall in FEV1. No significant differences in kJ were found between PL and ML trials for pooled subjects (95.3 ± 13.69 and 94.8 ± 13.27 kJ, respectively), EIB− subjects (99.6 ± 13.26 and 99.0 ± 11.81 kJ, respectively), or EIB+ subjects (86.8 ± 10.67 and 86.5 ± 12.72 kJ, respectively). Total work accumulated for EIB− subjects was significantly greater than for EIB+ subjects for both PL and ML (P < 0.05).
Conclusion: A single 10-mg dose of ML had no ergogenic effect for EIB− and EIB+ subjects performing short-duration high-intensity exercise in subfreezing temperature, supporting the use of ML as EIB prophylaxis during international sport competition.
1Human Performance Laboratory, Keith J. O’Neill Center for Healthy Families, Marywood University, Scranton, PA
2Human Performance Laboratory, Department of Kinesiology, University of Connecticut, Storrs, CT
Address for correspondence: Kenneth W. Rundell, Ph.D., Center for Healthy Families, Marywood University, Scranton, PA 18509; E-mail: firstname.lastname@example.org.
Submitted for publication May 2004.
Accepted for publication July 2004.